A natural history study of late onset spinal muscular atrophy types 3b and 4

被引:96
作者
Piepers, S. [1 ]
van den Berg, L. H. [1 ]
Brugman, F. [1 ]
Scheffer, H. [2 ]
Ruiterkamp-Versteeg, M. [2 ]
van Engelen, B. G. [3 ]
Faber, C. G. [4 ]
de Visser, M. [5 ]
van der Pol, W. -L. [1 ]
Wokke, J. H. J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, NL-3508 GA Utrecht, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands
[4] Univ Med Ctr, Dept Neurol, Maastricht, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands
关键词
spinal muscular atrophy; natural history; survival motor neuron;
D O I
10.1007/s00415-008-0929-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron (SMN) 1 gene. The nearly identical SMN2 gene plays a disease modifying role. SMA is classified into four different subtypes based on age of onset and clinical course (SMA types 1-4). The natural history of early onset SMA types 1-3a has been studied extensively. Late onset SMA is rare and disease course has not been studied in detail. Objective To perform a prospective study on the clinical course and the correlation with SMN2 copy numbers of late onset SMA. Methods Patients fulfilling the diagnostic criteria for late onset SMA (types 3b and 4) were included in the study. At inclusion and follow-up, muscle strength, respiratory function, functional status and quality of life were assessed. SMN2 copy number was determined in all patients Results Twelve patients were identified and included. Six patients were siblings from one family, two patients were brothers from a second family and four patients were sporadic cases. All patients carried four copies of the SMN2 gene. Median age of disease onset was 22.2 years (10-37). Age of disease onset in patients from family one was lower as compared to the other patients. None of the outcome measures changed after a follow-up of 2.5 years. Five patients reported an increase in fatigue and muscle weakness. None of the patients showed symptoms of respiratory insufficiency. Conclusions This study indicates that late onset SMA is not characterized by disease progression and that alternative or surrogate disease markers are required for the design of future trials. This study confirms the finding that SMN2 copy number is a SMA disease course modifier.
引用
收藏
页码:1400 / 1404
页数:5
相关论文
共 28 条
[1]  
*AM LAT SCL FUNCT, ARCH NEUROL, V53, P141
[2]   Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients [J].
Brahe, C ;
Vitali, T ;
Tiziano, FD ;
Angelozzi, C ;
Pinto, AM ;
Borgo, F ;
Moscato, U ;
Bertini, E ;
Mercuri, E ;
Neri, G .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (02) :256-259
[3]   Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy [J].
Brichta, L ;
Hofmann, Y ;
Hahnen, E ;
Siebzehnrubl, FA ;
Raschke, H ;
Blumcke, I ;
Eyupoglu, IY ;
Wirth, B .
HUMAN MOLECULAR GENETICS, 2003, 12 (19) :2481-2489
[4]   In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate [J].
Brichta, Lars ;
Holker, Irmgard ;
Haug, Karsten ;
Klockgether, Thomas ;
Wirth, Brunhilde .
ANNALS OF NEUROLOGY, 2006, 59 (06) :970-975
[5]   CLINICAL-TRIAL IN DUCHENNE DYSTROPHY .1. THE DESIGN OF THE PROTOCOL [J].
BROOKE, MH ;
GRIGGS, RC ;
MENDELL, JR ;
FENICHEL, GM ;
SHUMATE, JB ;
PELLEGRINO, RJ .
MUSCLE & NERVE, 1981, 4 (03) :186-197
[6]  
Brooks D, 2003, AM J RESP CRIT CARE, V167, P1287, DOI 10.1164/ajrccm.167.9.950
[7]   Spinal muscular atrophy: Survival pattern and functional status [J].
Chung, BHY ;
Wong, VCN ;
Ip, P .
PEDIATRICS, 2004, 114 (05) :E548-E553
[8]   CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy [J].
Escolar, DM ;
Buyse, G ;
Henricson, E ;
Leshner, R ;
Florence, J ;
Mayhew, J ;
Tesi-Rocha, C ;
Gorni, K ;
Pasquali, L ;
Patel, KM ;
McCarter, R ;
Huang, J ;
Mayhew, T ;
Bertorini, T ;
Carlo, J ;
Connolly, AM ;
Clemens, PR ;
Goemans, N ;
Iannaccone, ST ;
Igarashi, M ;
Nevo, Y ;
Pestronk, A ;
Subramony, SH ;
Vedanarayanan, VV ;
Wessel, H .
ANNALS OF NEUROLOGY, 2005, 58 (01) :151-155
[9]   Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy [J].
Feldkötter, M ;
Schwarzer, V ;
Wirth, R ;
Wienker, TF ;
Wirth, B .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 70 (02) :358-368
[10]   SURVIVAL MOTOR-NEURON GENE TRANSCRIPT ANALYSIS IN MUSCLES FROM SPINAL MUSCULAR-ATROPHY PATIENTS [J].
GENNARELLI, M ;
LUCARELLI, M ;
CAPON, F ;
PIZZUTI, A ;
MERLINI, L ;
ANGELINI, C ;
NOVELLI, G ;
DALLAPICCOLA, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (01) :342-348